Search for: "Sanofi-Aventis US Inc"
Results 61 - 80
of 160
Sort by Relevance
|
Sort by Date
23 Nov 2011, 1:13 pm
Sanofi-aventis Canada Inc., in collaboration with Health Canada, would like to inform patients of important safety information related to the use of the heart drug Multaq (dronedarone).... (12/13/11) ______________________________________________________________________________ In mid-June 2011 drug regulators first turned their attention to cardiovascular side effects associated with the use of Multaq (dronedarone), soon after… [read post]
18 Oct 2011, 8:31 am
” Sanofi- Aventis v. [read post]
15 Sep 2011, 5:00 am
Sanofi-Aventis U.S. [read post]
10 Aug 2011, 4:30 am
(Patent Docs) Prezista (Darunavir) – US: Patent infringement complaint filed following a Paragraph IV certification: Tibotec Inc. et al. v. [read post]
3 Aug 2011, 3:31 am
Application fee increases by a whopping 19.4% (or almost $300K) (FDA Law Blog) US: Life sciences venture funding up 37% in second quarter (Patent Docs) Products Arava (Leflunomide) – Australia: FCA ‘evergreens’ Arava: Sanofi-Aventis Australia v Apotex (Patentology) Cambia (Diclofenac) – US: Nautilus files patent infringement complaint against Edict Pharmaceuticals in response to Para IV certification filing (Patent Docs) Cenestin… [read post]
22 Jul 2011, 2:34 pm
" (8/4/11, Health Canada MedEffect e-Notice) Multaq (dronedarone), Sanofi-aventis Canada Inc., must not be prescribed to patients with permanent atrial fibrillation. [read post]
10 Jul 2011, 11:29 pm
The committee is seeking documents and information from Amphastar Pharmaceuticals, Momenta Pharmaceuticals, Siegfried USA Inc., Sagent Pharmaceutical, APP Pharmaceuticals, Sanofi Aventis, Drug Source Company LLC, Global Pharma Sourcing LLC, Pacific Rainbow International and Sandoz. [read post]
8 Jul 2011, 11:04 am
IMS Health Inc., ___ U.S. ___, 2011 WL 2472796, at *8 (U.S. [read post]
29 Jun 2011, 3:34 am
Cipla (Spicy IP) Effexor (Venlafaxine) – US: Intellipharmaceutics announces settlement for its generic version of Effexor (GenericsWeb) Eloxatin (Oxaliplatin) – US: Patent infringement complaint in response to Para IV certification: Sanofi-Aventis U.S. [read post]
25 May 2011, 8:52 pm
Therasense, Inc. v. [read post]
20 May 2011, 8:53 am
Sanofi-Aventis U.S. [read post]
15 May 2011, 2:54 pm
Karst – Last week, the Federal Trade Commission (“FTC”) announced that the Commission’s Bureau of Competition (“Bureau”) sent letters (here, here, and here) to Sanofi-Aventis U.S. [read post]
2 Apr 2011, 11:58 pm
Sanofi-Aventis U.S. [read post]
15 Mar 2011, 3:52 pm
Judge Susan Illston recently granted summary judgment on a few claims but left others for trial in a massive pharmaceutical patent case between Sanofi-Aventis Deutchland GMBH (Sanofi, plaintiff), Genentech, Inc. [read post]
18 Feb 2011, 11:47 am
The defendants in both sets of actions were Sanofi Aventis and Sanofi-Synthelabo, Inc., Bristol-Myers Squibb Company and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively “Sanofi”) and Apotex Corporation (“Apotex”). [read post]
8 Feb 2011, 10:51 pm
(FDA Law Blog) US: Another academic with solutions to problems that don’t exist (Patent Docs) US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs) US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report) US: District Court New… [read post]
9 Jan 2011, 9:09 pm
USA 1:11-cv-00018; filed January 6, 2011 in the District Court of Delaware • Plaintiffs: Aventis Pharma S.A.; Sanofi-Aventis U.S. [read post]
29 Dec 2010, 2:57 am
Ferring Pharmaceuticals, Inc et al. [read post]
14 Dec 2010, 7:06 pm
Karst – When we last left you in the battle over FDA’s approval of a generic version of sanofi-aventis U.S. [read post]
8 Dec 2010, 6:07 pm
The medications include Abbott Laboratories Inc's Lupron, AstraZeneca's Zoladex and Sanofi-Aventis SA's Eligard.According to the FDA, the drugs, known as gonadotropin-releasing hormone (GnRH) agonists, are used to suppress the production of testosterone, a hormone that helps fuel prostate cancer growth. [read post]
